Biblio
B
Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJosee, Böhmer LH, Minnema MC, MacKenzie MA, Kooij Rvan Marwij, de Jongh E, Snijders TJF, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020.
C
Sureda A, Lugtenburg PJ, Kersten MJosé, Subklewe M, Spanjaart A, Shah NN, Kerbauy LN, Roddie C, Pennings ERA, Mahuad C, et al. Cellular therapy in lymphoma. Hematol Oncol. 2023.
R
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, de Graauw NC van der, Schouten HC, Bilgin YM, et al. Rituximab-PECC induction followed by Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019.